ETNB 89bio, Inc.

Nasdaq 89bio.com


$ 14.75 $ -0.01 (-0.07 %)    

Friday, 17-Oct-2025 15:59:53 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 14.76
$ 14.77
$ 14.70 x 10
$ 14.83 x 29
$ 14.74 - $ 14.79
$ 4.16 - $ 15.06
1,714,507
na
2.19B
$ 1.32
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2025 06-30-2025 10-Q
2 05-02-2025 03-31-2025 10-Q
3 02-27-2025 12-31-2024 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-05-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-01-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-09-2023 06-30-2023 10-Q
10 05-08-2023 03-31-2023 10-Q
11 03-15-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-24-2022 12-31-2021 10-K
16 11-12-2021 09-30-2021 10-Q
17 08-13-2021 06-30-2021 10-Q
18 05-14-2021 03-31-2021 10-Q
19 03-25-2021 12-31-2020 10-K
20 11-13-2020 09-30-2020 10-Q
21 08-13-2020 06-30-2020 10-Q
22 05-13-2020 03-31-2020 10-Q
23 03-18-2020 12-31-2019 10-K
24 12-18-2019 09-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Roche ((SIX: RO, ROG, OTCQX:RHHBY) announced today that it has commenced a tender offer for all of the outstanding shares of co...

 raymond-james-downgrades-89bio-to-market-perform

Raymond James analyst Steven Seedhouse downgrades 89bio (NASDAQ:ETNB) from Outperform to Market Perform.

 deal-dispatch-need-ma-approval-fcc-chair-explains-how-to-get-it

The "Jimmy Kimmel Live" drama coincided with reports of tit-for-tat maneuvering between the FCC and corporations desper...

 wolfe-research-downgrades-89bio-to-peer-perform

Wolfe Research analyst Andy Chen downgrades 89bio (NASDAQ:ETNB) from Outperform to Peer Perform.

 hc-wainwright--co-downgrades-89bio-to-neutral-announces-145-price-target

HC Wainwright & Co. analyst Andrew S. Fein downgrades 89bio (NASDAQ:ETNB) from Buy to Neutral and announces $14.5 price ...

 russell-2000-hits-all-time-highs-8-stocks-power-small-cap-comeback

Small-cap benchmark Russell 2000 ETF hits record high after Fed cuts rates, hinting at more cuts. Small caps rally 43% since ta...

 roche-to-acquire-89bio-for-24-billion-in-liver-and-cardiometabolic-push

Roche is acquiring 89bio for $2.4 billion plus potential milestone payouts, bolstering its pipeline with late-stage MASH drug p...

 stock-market-today-sp-500-nasdaq-futures-rise-following-fed-rate-cuts-nvidia-and-intel-in-focus-after-5-billion-investment-deal-updated

U.S. stock futures advanced on Thursday following Wednesday's mixed moves. Futures of major benchmark indices were higher.

 darden-restaurants-factset-research-and-3-stocks-to-watch-heading-into-thursday

U.S. stock futures trading higher, stocks to watch: Darden, Bullish, Factset. 89bio acquired by Roche. FedEx Q1 earnings expected.

Core News & Articles

89bio's pegozafermin allows for a potentially best-in-disease treatment for moderate to severe Metabolic Dysfunction-Associ...

 hc-wainwright--co-assumes-89bio-at-buy-announces-price-target-of-32

HC Wainwright & Co. analyst Andrew S. Fein assumes 89bio (NASDAQ:ETNB) with a Buy rating and announces Price Target of $32.

 b-of-a-securities-maintains-buy-on-89bio-lowers-price-target-to-29

B of A Securities analyst Alexandria Hammond maintains 89bio (NASDAQ:ETNB) with a Buy and lowers the price target from $30 t...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION